

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO	
10/526,780	05/20/2005	Akihiko Kitajima	2005-0265A	8813	
513	7590 07/10/2006		EXAMINER		
	TH, LIND & PONAC	SPIVACK, PHYLLIS G			
2033 K STRE SUITE 800	ET N. W.	ART UNIT	PAPER NUMBER		
WASHINGTON, DC 20006-1021			1614		
			DATE MAILED: 07/10/2006		

Please find below and/or attached an Office communication concerning this application or proceeding.

		Applicati	on No.	Applicant(s)				
Office Action Summary		10/526,7	30	KITAJIMA ET AL.				
		Examine	,	Art Unit				
		Phyllis G.	Spivack	1614				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply								
A SH WHIC - Exter after - If NC - Failu Any I	ORTENED STATUTORY PERIOD FOR CHEVER IS LONGER, FROM THE MANAGER OF	MAILING DATE OF The sof 37 CFR 1.136(a). In no evenunication. Itatutory period will apply and we will, by statute, cause the approximation.	HIS COMMUNICATION ent, however, may a reply be timil expire SIX (6) MONTHS from dication to become ABANDONE	N. sely filed the mailing date of this co D (35 U.S.C. § 133).				
Status								
1)	Responsive to communication(s) fil	ed on						
′	•	2b)⊠ This action is r	on-final.					
3)□	Since this application is in condition	nce this application is in condition for allowance except for formal matters, prosecution as to the merits is						
	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.							
Dispositi	on of Claims							
4)⊠	4)⊠ Claim(s) <u>1-10</u> is/are pending in the application.							
-	4a) Of the above claim(s) is/are withdrawn from consideration.							
5)	5) Claim(s) is/are allowed.							
6)□	Claim(s) is/are rejected.							
•	Claim(s) is/are objected to.							
8)⊠	Claim(s) <u>1-10</u> are subject to restrict	ion and/or election red	quirement.					
Applicati	on Papers							
9) The specification is objected to by the Examiner.								
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.								
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).								
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).								
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.								
Priority u	nder 35 U.S.C. § 119							
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 								
	2. Certified copies of the priority documents have been received in Application No							
	3. Copies of the certified copies of the priority documents have been received in this National Stage							
application from the International Bureau (PCT Rule 17.2(a)).								
* S	ee the attached detailed Office action	on for a list of the cert	fied copies not receive	d.				
Attachmen	Ne)							
Attachment(s) 1) Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413)								
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)			Paper No(s)/Mail Da	ate				
	nation Disclosure Statement(s) (PTO-1449 o r No(s)/Mail Date	r PTO/SB/08)	5) Notice of Informal P 6) Other:	atent Application (PTC)-152)			

Application/Control Number: 10/526,780

Art Unit: 1614

Restriction to one of the following inventions is required under 35 U.S.C. 121:

I. Claims 1, 2 and 5-10, drawn to compounds, compositions and methods of preparation, Class 548, subclass 400+, and class 514, subclass 423.

II. Claims 3 and 4, drawn to methods for promoting the movement of the digestive tract comprising administering 4-amino-5-chloro-2-methoxy-N-[(2S,4S)-2-hydroxymethyl-4-pyrrolidinyl]benzamide, Class 514, subclass 423.

The Groups are distinct, each from the other, for the following reasons.

Inventions I and II are related as product and process of making, and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product. See MPEP § 806.05(h). In the instant case the process for using the product, i.e., for improving the movement of the digestive tract, can be practiced with another materially different product, such as any stimulant laxative.

The Groups have acquired a separate status in the art as shown by their recognized, divergent subject matter. The searches required for each Group are not coextensive resulting in an undue burden to the Examiner. Each Group is capable of supporting a separate patent.

Restriction for examination purposes as indicated is proper.

Page 3

Application/Control Number: 10/526,780

Art Unit: 1614

Should Applicants traverse on the ground that the species are not patentably distinct, Applicants should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the Examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Where the Examiner has required restriction between product and process claims and Applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04. Process claims that depend from or otherwise include all the limitations of the patentable product will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after Final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103, and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined. See "Guidance on Treatment of Product and Process Claims in light of In re Ochiai, In re Brouwer and 35 U.S.C. § 103(b)," 1184 O.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy. Applicant is advised that the process claims should be amended during prosecution either to maintain dependency on the product claims or to otherwise include the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder. Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the Examiner before the patent issues withdraws the restriction requirement. See MPEP § 804.01.

Application/Control Number: 10/526,780

Art Unit: 1614

Applicants are advised that to be complete, the reply to this requirement must include an election of the invention to be examined even though the requirement is traversed (37 CFR 1.143).

A telephone call to the attorney is not required where: 1) the restriction requirement is complex; 2) the application is being prosecuted *pro se*; or, 3) the Examiner knows from past experience that a telephone election will not be made. See MPEP 812.01.

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Phyllis G. Spivack whose telephone number is 571-272-0585. The Examiner can normally be reached on 10:30 AM-7 PM.

If attempts to reach the Examiner by telephone are unsuccessful after one business day, the Examiner's supervisor, Ardin Marschel, can be reached on 718. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/526,780 Page 5

Art Unit: 1614

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

July 1, 2006

Phyllis G. Spivack

Phyllis G. Spivack

PHYLLIS SPIVACK
PRIMARY EXAMINER